Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study

Hagberg, HansKarolinska Institutet,Uppsala universitet,Experimentell och klinisk onkologi (författare)

Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line rituximab was gradually introduced between 2003 and 2007, with regional differences. The first national guidelines for FL were published in November 2007, recommending rituximab in first-line therapy. Using the population-based Swedish Lymphoma Registry, 2641 patients diagnosed with FL from 2000 to 2010 were identified and characterized by year and region of diagnosis, age (median, 65 years), gender (50% men), first-line therapy and clinical risk factors. Overall and relative survivals were estimated by calendar periods (2000-2002, 2003-2007 and 2008-2010) and region of diagnosis. With each period, first-line rituximab use and survival increased. Survival was superior in regions where rituximab was quickly adopted and inferior where slowly adopted. These differences were independent in multivariable analyses. Ten-year relative survival for patients diagnosed 2003-2010 was 92%, 83%, 78% and 64% in the age groups 18-49, 50-59, 60-69 and ≥70, respectively. With increasing rituximab use, male sex emerged as an adverse factor. Survival improved in all patient categories, particularly in elderly women. The introduction and the establishment of rituximab have led to a nationwide improvement in FL survival. However, rituximab might be inadequately dosed in younger women and men of all ages. © 2015 Macmillan Publishers Limited. All rights reserved.

Peterson, StefanLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-sfp (författare)
Kimby, E.Karolinska Institutet (författare)
Lockmer, S.Karolinska Institutet (författare)
Lindén, OlaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)onk-oli (författare)
Nilsson-Ehle, Herman,1950Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition(Swepub:gu)xnilsh (författare)
Erlanson, MartinUmeå universitet,Onkologi(Swepub:umu)maer0058 (författare)
Hagberg, OskarLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)mats-oha (författare)
Rådlund, A. (författare)
Hagberg, O. (författare)
Wahlin, B. E.Karolinska Institutet (författare)
Uppsala universitetExperimentell och klinisk onkologi (creator_code:org_t)

Ingår i:Leukemia: Springer Science and Business Media LLC29:3, s. 668-6760887-69241476-5551

Av författaren/redakt...: Hagberg, Hans; Peterson, Stefan; Kimby, E.; Lockmer, S.; Lindén, Ola; Nilsson-Ehle, He ...; visa fler...; Erlanson, Martin; Hagberg, Oskar; Rådlund, A.; Hagberg, O.; Wahlin, B. E.; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Av lärosätet: Göteborgs universitet; Lunds universitet; Uppsala universitet; Umeå universitet; Karolinska Institutet

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.